ABUS News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AB

Mkt Cap

$837.0M

Volume

2.71M

Next Earnings

November 12th

Loading chart

AB

ABUSArbutus Biopharma Corporation Common Stock

ABUS

Pay with—

Available Balance0.00

AB

Mkt Cap

$849.9M

Volume

2.71M

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

9 Biotech Stocks Trading Far Below Fair Value With Up to 250% Upside PotentialModerna settled a long-running legal dispute over COVID-19 vaccine technology, paying $2.25 billion to Roivant Sciences' Genevant unit and Arbutus Biopharma—less than the $3 billion expected. While Moderna stock surged 15.99% on the news, analysts suggest it now trades 22% above fair value after a 108% six-month rally. The article identifies 9 biotech stocks trading 27.6% to 64.6% below fair value with potential upside of 31.6% to 251.4%.Investing.com · Mar 5, 2026

Moderna's $950 Million Settlement Clears Legal Overhang, Stock SoarsModerna reached a $950 million settlement agreement with Arbutus Biopharma and Roivant's Genevant Sciences, resolving litigation related to its COVID-19 vaccine Spikevax and mRESVIA product. The settlement clears a major legal overhang, allowing the company to focus on future growth. Moderna expects to end 2026 with $4.5-5 billion in cash and aims for breakeven in 2028. The stock surged 8.85% in premarket trading as the settlement value was better than investors' worst-case fears.Benzinga · Mar 4, 2026

Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So.Moderna's stock has been struggling since the end of the COVID-19 pandemic, with a Wall Street analyst cutting her price target and reiterating a sell recommendation. The analyst cited issues such as cost-management struggles and legal headaches, as well as a hold on a late-stage trial for a norovirus vaccine candidate.The Motley Fool · Feb 20, 2025

Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last?Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.Zacks Investment Research · Jun 13, 2024

Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg LevelsData highlighted in oral presentation at the European Association for the Study of the Liver (EASL) CongressGlobeNewswire Inc. · Jun 6, 2024

Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional CureAt the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were maintained in 100% of these patients 24 weeks after completing imdusiran and IFN treatmentGlobeNewswire Inc. · Jun 5, 2024

Arbutus to Participate in Jefferies Global Healthcare ConferenceWARMINSTER, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will present at and host one-on-one meetings at the following upcoming investor conference being held in New York:GlobeNewswire Inc. · May 29, 2024

Arbutus to Present Imdusiran Data at EASL Congress 2024WARMINSTER, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that two abstracts have been accepted for poster and oral presentations at the European Association for the Study of the Liver (EASL) Congress 2024 taking place June 5 - 8, 2024 in Milan, Italy.GlobeNewswire Inc. · May 22, 2024

Arbutus to Participate in Two Upcoming Investor ConferencesWARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in New York:GlobeNewswire Inc. · May 7, 2024

Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue EstimatesArbutus (ABUS) delivered earnings and revenue surprises of 0% and 28.91%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · May 2, 2024

to start trading

AB

ABUSArbutus Biopharma Corporation Common Stock

ABUS

Pay with—

Available Balance0.00

Your PositionYou don't own any ABUS yet.

Related Tickers

Earnings